{
}
UBS AG has maintained a "Neutral" rating for Bayer, setting a target price of 30 euros after the company reported quarterly figures that fell short of expectations. Following the announcement, Bayer shares dropped 11.2% to EUR 21.69, reflecting a 35.3% decline since the start of 2024, with a potential upside of 38.34% to the target price. The next financial results are anticipated on November 12, 2024.
UBS AG has maintained a "Neutral" rating on Bayer shares with a target price of €30, following disappointing quarterly results that fell short of consensus estimates. As of the latest trading session, Bayer shares dropped 11.3% to €21.67, indicating a potential upside of 38.44% from the target price. The company is set to release its Q3 2024 financial results on November 12, 2024.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted a slight upward trend in prescriptions for the weight loss drug Wegovy in the USA, especially after its recent removal from the list of scarce drugs. Since its initial recommendation, Novo Nordisk's stock has risen by 4.270%.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Analyst Jo Walton noted a slight upward trend in prescriptions for the weight loss drug Wegovy in the USA, with data expected to improve following its removal from the list of scarce drugs.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton projects a growth rate of 23% for 2025, surpassing the market's expectation of 20%. Novo Nordisk has seen a remarkable 4,176% increase since its initial recommendation.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a price target of 1,100 Danish crowns. Analyst Jo Walton projects a growth rate of 23% for 2025, slightly above the market expectation of 20%. The analysis follows discussions among analysts regarding the company's future growth prospects.
UBS has maintained a 'Neutral' rating for Bayer, setting a target price of 30 euros. The Crop Science division typically experiences losses in the third quarter, while the pharmaceuticals sector is expected to perform strongly. Bayer's initial outlook for 2025 has fallen short of market expectations.
UBS has maintained a 'Neutral' rating for Bayer, setting a target price of 30 euros. The Crop Science division typically incurs losses in Q3, while the pharmaceuticals sector performs well. Bayer's initial outlook for 2025 fell short of market expectations. Sales distribution shows agricultural products at 48.8%, pharmaceuticals at 38%, OTC products at 12.7%, and other at 0.5%. Geographically, the U.S. accounts for 30.6% of sales, with significant contributions from Europe, Asia, and Latin America.
UBS has maintained a 'Neutral' rating for Bayer, setting a target price of 30 euros. The third quarter typically sees losses in the Crop Science division, while the pharmaceutical sector performs strongly. Bayer's initial outlook for 2025 has fallen short of market expectations. As of November 7, 2024, Bayer's stock is trading at approximately 24.37 euros, reflecting a 1.75% increase.
UBS has maintained a 'Neutral' rating for Novo Nordisk with a target price of 1100 Danish crowns. Despite the company's forecast of high growth for 2025, UBS's estimates are lower than market expectations, leading to a notable fluctuation in share prices following the announcement.
Jo Walton
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Bayer shares drop as UBS maintains neutral rating after quarterly results
11:34 12.11.2024
ubs maintains neutral rating on bayer shares with target price of 30 euros
10:34 12.11.2024
UBS maintains neutral rating for Novo Nordisk with target price of 1100 kroner
15:50 11.11.2024
ubs maintains neutral rating on novo nordisk with target price of 1100 kroner
14:52 11.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
20:22 07.11.2024
ubs maintains neutral rating for novo nordisk with 1100 kroner target
20:22 07.11.2024
ubs maintains neutral rating for bayer with target price of 30 euros
19:31 07.11.2024
ubs maintains neutral rating for bayer with target price of 30 euros
19:31 07.11.2024
ubs maintains neutral rating for bayer with target price of 30 euros
18:44 07.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
Danish Krone
UBS AG
Novo Nordisk A/S
DNK
Hubert Dichtl
Warren Buffet
Thomas Müller
Jo Walton
Show more
21:07 06.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Central Bank Actions
Finance Mergers & Acquisitions
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Government Economic Policies
CEO Changes
Market Analysis and Predictions
Domestic Politics
Government Policies
Workplace Trends
GDP Growth & Recession Forecasts
Financial Scams and Security
Countries:
Companies:
Tesla, Inc.
Apple Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
Credit Suisse Strategic Income I
Banco Santander, S.A.
Berkshire Hathaway Inc.
SpaceXCoin USD
Bank of America Corporation
Morgan Stanley
BNP Paribas SA
Amazon.com, Inc.
UBS Group AG
Lloyds Banking Group plc
NVIDIA Corporation
Bank Frick AG
Citigroup Inc.
Wells Fargo & Company
Currencies:
United States Dollar
Euro
British Pound Sterling
Japanese Yen
Swiss Franc
Indian Rupee
Chinese Yuan
South Korean Won
Vietnamese Đồng
Canadian Dollar
Australian Dollar
Thai Baht
Indonesian Rupiah
Singapore Dollar
Mexican Peso
New Taiwan Dollar
Russian Ruble
Hong Kong Dollar
Offshore Chinese Yuan
New Zealand Dollar
People: